Michael Grundman, MD, MPH
Clinical Development Leader
Michael Grundman is the leader of clinical strategy and product development at Proclara, and serves as the president and chief executive officer at Global R&D Partners, a consulting firm that works closely with pharmaceutical and biotechnology companies to develop novel agents for the diagnosis and treatment of serious and life-threatening diseases. Additionally, he is currently a professor of neurosciences at the University of California, San Diego. Grundman was previously the vice president of clinical development at Janssen Alzheimer Immunotherapy Research and Development and the vice president of clinical development at Elan Pharmaceuticals. Prior to joining industry, Grundman was the Associate Director of the Alzheimer’s Disease Cooperative Study (ADCS) at the University of California, San Diego. He received his Bachelor of Arts in Biochemistry from New York University, his Doctor of Medicine from the Albert Einstein College of Medicine, where he also completed training in neurology, and received his Master of Public Health degree from Columbia University.
Grundman is an inventor on a number of patents related to Alzheimer’s disease therapy and has served on the FDA Peripheral and Central Nervous System Advisory Committee.